Drug Profile
Research programme: cytomegalovirus DNA polymerase inhibitors - Pharmacia
Alternative Names: Cytomegalovirus DNA polymerase inhibitors research programme - PharmaciaLatest Information Update: 02 Aug 2002
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 04 May 2000 New profile
- 04 May 2000 Preclinical development for Cytomegalovirus infections in USA (Unknown route)